Ophthalmology

The new approval allows for repeat administration of iDose TR, modifying the existing single-administration label.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and CRLs, in this week’s essential news roundup.

The CRL notes that additional mechanistic and natural history data have not altered the previous review conclusions.

Catch up on the most impactful headlines in ophthalmology from all of 2025 with our Year in Review.

The FDA’s decision is based on positive results from the phase 3 THRIVE and THRIVE-2 clinical trials, which showed veligrotug’s efficacy and rapid onset of benefits.

Following the addition of a clinical study report to the NDA on December 12, the regulatory agency has extended the review period for the RASP inhibitor.

In a cross-sectional OCTA analysis of patients with referable diabetic retinopathy, CKD emerges as an independent predictor of higher MA burden.

Catch up on the groundbreaking FDA approvals, key trial updates, and more news from the last month.

Based on results from the THRIVE and THRIVE-2 phase 3 studies, this Biologics License Application includes a request for Priority Review.

Following a Type A meeting with the FDA, the ophthalmic formulation of bevacizumab is back on track towards a potential US approval.

A secondary analysis of the J-DOIT3 study highlights previously undertreated factors in the progression of diabetic retinopathy in patients with type 2 diabetes.

In a post-hoc analysis of the KINGFISHER trial, brolucizumab resulted in improved BCVA and anatomical outcomes regardless of prior anti-VEGF treatment.

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

This approval represents an alternative method for approaching this undertreated disease, shortening recovery while minimizing invasiveness.

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.

Outlook Therapeutics has expressed plans to meet with the FDA to address regulatory issues, as well as expand into European markets.

A brief history of intravitreal implants; where we started and how far we can still go to reduce treatment burden for patients and clinicians alike.

This HCPLive Five episode focuses on 5 key ophthalmology updates from the ASRS2025 conference.

Stay updated with the latest healthcare breakthroughs, including an FDA approval and new clinical trial data, in this week's essential news roundup.

A month with few regulations instead saw significant research advancements presented at the American Society of Retina Specialists’ 2025 meeting.